Anti-Rheumatic Drugs - Fiji | Statista Market Forecast

The Anti-Rheumatic Drugs market in Fiji is expected to experience significant growth in the coming years.
By 2024, revenue in this market is projected to reach US$446.40k.
Furthermore, it is anticipated that the market will continue to expand with an annual growth rate of 0.73% from 2024 to 2029.
This growth will result in a market volume of US$462.90k by the end of 2029.
When comparing in Fiji to other countries globally, it is worth noting that United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024, the revenue United States is projected to reach a staggering US$34.70bn.
This highlights the dominance of the United States in this market on a global scale.
The demand for anti-rheumatic drugs in Fiji is on the rise, as the country's aging population continues to grapple with chronic rheumatic conditions.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Fiji has been experiencing significant growth in recent years.

Customer preferences: Fijians are becoming increasingly aware of the importance of managing rheumatic diseases, and are seeking out effective treatments to manage their symptoms. As a result, there has been a growing demand for anti-rheumatic drugs in the country. Patients are also becoming more proactive in their healthcare, and are taking an active role in managing their conditions.

Trends in the market: One of the key trends in the Anti-Rheumatic Drugs market in Fiji is the increasing availability of biologic drugs. These drugs are highly effective in managing rheumatic diseases, and are becoming more widely available in the country. There has also been a growing trend towards combination therapy, where patients are prescribed multiple drugs to manage their symptoms. This approach can be more effective than using a single drug, and is becoming more popular among healthcare providers in Fiji.

Local special circumstances: One of the unique challenges facing the Anti-Rheumatic Drugs market in Fiji is the limited availability of healthcare resources in the country. This can make it difficult for patients to access the care and medication they need, particularly in rural areas. In addition, there is a lack of rheumatologists in the country, which can make it challenging for patients to receive specialized care.

Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Fiji is being driven by a number of underlying macroeconomic factors. One of the key drivers is the country's aging population. As Fijians live longer, the prevalence of rheumatic diseases is increasing, driving demand for anti-rheumatic drugs. In addition, the country's growing middle class is also contributing to the growth of the market. As incomes rise, more people are able to afford healthcare and medication, further driving demand for anti-rheumatic drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.